[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Janssen Korea, Ltd., Korea\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100632981","a-database-study-of-disease-treatment-patterns-and-healthcare-use-in-children-with-inflammatory-bowel-diseases-in-korea-100632981",false,"NCT07520747","A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea","Epidemiology, Treatment Patterns, and Healthcare Resource Utilization in Pediatric Patients Under 18 Years of Age With Inflammatory Bowel Diseases in Korea: A Claims Database Study","Ped IBD Claims","Inclusion Criteria:\n\n* Participants with at least two outpatient or one inpatient diagnosis codes for the same disease type (either CD or UC) using international classification of diseases, tenth revision (ICD-10) codes (K50. X for CD and K51. X for UC) recorded as primary or the first secondary diagnosis, and the codes for rare and intractable disease registration program (V130 for CD, V131 for UC) during the index period\n* Participants who received at least one prescription for conventional pediatric inflammatory bowel disease (IBD)-related medications (for example, 5-aminosalicylic acids \\[5-ASAs\\], exclusive enteral nutrition \\[EENs\\], corticosteroids, immunomodulators, or biologic drugs) during the index period\n\nExclusion Criteria:\n\n\\- No specific exclusion criteria are defined in this study","ALL","17 Years",{"count":20,"type":21},8000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is:\n\n* to find out out the number of children who develop crohn's disease (CD) and ulcerative colitis (UC) each year and are living with the disease and to see how this differs by age groups.\n* to understand how children of different age groups are treated over time and how their treatment changes as they grow.\n* to assess how often children use healthcare services and how much this costs for different age groups over several years.\n\nCD and UC are long-term diseases that cause inflammation in intestine (part of digestive system) and develop ulcers.",[25],"Inflammatory Bowel Diseases","RECRUITING","2026-06-04",{"date":29,"type":30},"2026-06-05","ACTUAL",{"date":32,"type":30},"2026-04-07",{"date":34,"type":21},"2026-06-29",{"name":36,"class":37},"Janssen Korea, Ltd., Korea","INDUSTRY",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100597042","phase-4-a-study-of-esketamine-nasal-spray-in-korean-participants-with-treatment-resistant-depression-100597042","NCT07053345","A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression","An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Esketamine Nasal Spray in Korean Participants With Treatment-Resistant Depression(TRD)","Inclusion Criteria:\n\n* Must have a confirmed diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition at the time of enrollment, without psychotic features, based on clinical assessment, and confirmed by mini international neuropsychiatric interview (MINI)\n* Must have a Hamilton depression rating scale (HAM-D; 17-item) total score greater than or equal to (\\>=) 22 at screening and Day 1\n* Participants must have had non-response (less than or equal to \\[\\\u003C=\\] 25 percent \\[%\\] improvement of symptoms) to \\>= 2 oral antidepressant treatments in the current moderate to severe episode of depression after having been given at an adequate dosage for an adequate duration of at least 6 weeks\n* At baseline (Day 1), the investigator will evaluate any changes in the participant's signs\u002Fsymptoms of depression since the screening assessment and confirm that the inclusion criteria for the current antidepressant (AD) treatment are still met (that is, nonresponse and minimal clinical improvement)\n* A female participant of childbearing potential must have a negative serum pregnancy test at screening and urine prior to the first dose of study intervention on Day 1\n\nExclusion Criteria:\n\n* Participants with hyperthyroidism that has not been sufficiently treated\n* History of malignancy within 5 years of enrollment before screening\n* Known allergies, hypersensitivity, or intolerance to esketamine\u002Fketamine or its excipients\n* Received an investigational intervention or used an invasive investigational medical device within 60 days before the planned first dose of study intervention or first data collection time point\n* Currently enrolled in an investigational study that involves treatments for MDD or may otherwise be expected to impact mood","18 Years","64 Years",{"count":49,"type":21},47,"INTERVENTIONAL",[52],"PHASE4","The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD). This will be assessed by the change from baseline in the Hamilton depression rating scale (HAM-D; 17-item) total score from Day 1 (baseline) to the end of the 4-week treatment phase (Day 28).",[55],"Depressive Disorder, Treatment-Resistant",{"date":29,"type":30},{"date":58,"type":30},"2025-06-09",{"date":60,"type":21},"2027-06-25",{"name":36,"class":37},6,""]